


Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: <http://www.elsevier.com/locate/rpor>

## Corrigendum

## Corrigendum to “Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance”. [Rep. Pract. Oncol. Radiother. 20 (2015) 259–272]



José López Torrecilla<sup>a,\*</sup>, Asunción Hervás<sup>b</sup>, Almudena Zapatero<sup>c</sup>, Antonio Gómez Caamaño<sup>d</sup>, Víctor Macías<sup>e</sup>, Ismael Herruzo<sup>f</sup>, Xavier Maldonado<sup>g</sup>, Alfonso Gómez Iturriaga<sup>h</sup>, Francesc Casas<sup>i</sup>, Carmen González San Segundo<sup>j</sup>

<sup>a</sup> Servicio Oncología Radioterápica-ERESA, Hospital General Universitario, Valencia, Spain

<sup>b</sup> Radiation Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain

<sup>c</sup> Radiation Oncology Department, Hospital Universitario de la Princesa, Madrid, Spain

<sup>d</sup> Servicio de Oncología Radioterápica, Hospital Clínico Universitario Santiago de Compostela, Santiago de Compostela, Spain

<sup>e</sup> Servicio de Oncología Radioterápica, Hospital Universitario de Salamanca, Spain

<sup>f</sup> Servicio de Oncología Radioterápica, Hospital Regional Universitario Carlos Haya, Málaga, Spain

<sup>g</sup> Servicio de Oncología Radioterápica, Hospital Universitari Vall d'Hebron, Barcelona, Spain

<sup>h</sup> Servicio de Oncología Radioterápica, Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain

<sup>i</sup> Servicio Oncología Radioterápica, Hospital Clinic, Barcelona, Spain

<sup>j</sup> Servicio de Oncología Radioterápica, Hospital Universitario Gregorio Marañón, Madrid, Spain

The authors wish to indicate two corrections in the article referenced above:

- Fig. 3. Where it says “M1 symptomatic or minimally symptomatic”, should say “M1 asymptomatic or minimally symptomatic”.
- Table 3. Where it says “COU-AA-301: CRPC with metastasis, asymptomatic or minimally symptomatic prior to chemotherapy”, should say “COU-AA-302: CRPC with metastasis, asymptomatic or minimally symptomatic prior to chemotherapy”.

The authors apologise for these errors.

DOI of original article: <http://dx.doi.org/10.1016/j.rpor.2015.04.003>.

\* Corresponding author. Tel.: +34 963 131 911.


E-mail address: [jltorrecilla@eres.com](mailto:jltorrecilla@eres.com) (J. López Torrecilla).

<http://dx.doi.org/10.1016/j.rpor.2015.06.006>

1507-1367/© 2015 Published by Elsevier Sp. z o.o. on behalf of Greater Poland Cancer Centre.

**Table 3 – Results of phase III trials in patients with mCRPC and new drug combinations.**

Study	Control arm	Active drug arm	Months difference in OS
Ra 223	SUPPORT TREATMENT + PLACEBO 307 patients	Ra 223 + SUPPORT TREATMENT 614 patients	11.2 vs. 14 3.8 months
MDV 3100	PLACEBO ± CORTICOSTEROIDS 399 patients	MDV3100 ± CORTICOSTEROIDS 800 patients	13.6 vs. 18.4 4.8 months
ABIRATERONE	PREVAIL: mCRPC IN CHEMOTHERAPY NAIVE PLACEBO: 845 patients	MDV3100 872 patients	Enzalutamide reduced the risk of death by 29%. Study unblinded in 2013
ABIRATERONE	COU-AA-302: CRPC with metastasis, asymptomatic or minimally symptomatic prior to chemotherapy PLACEBO + CORTICOSTEROIDS 542 patients	ABIRATERONE + CORTICOSTEROIDS 546 patients	30.1 vs. 35.3 5.2 months
ABIRATERONE	COU-AA-301: CRPC with metastasis after chemotherapy PLACEBO + CORTICOSTEROIDS 398 patients	ABIRATERONE + CORTICOSTEROIDS 797 patients	11.2 vs. 15.8 months 4.6 months
CABAZITAXEL	TROPIC: CRPC with metastasis after chemotherapy MITOXANTRONE + CORTICOSTEROIDS 377 patients	CABAZITAXEL + CORTICOSTEROIDS 378 patients	12.7 vs. 15.1 2.4 months
SIPULEUCEL-T	IMPACT 301: CRPC with metastasis prior to chemotherapy PLACEBO 171 patients	SIPULEUCEL T 341 patients	21.7 vs. 25.8 4.1 months



**Fig. 3 – Imaging, treatment and follow-up algorithm for patients with castration-resistance prostate cancer.**